Clinical Trial Update: Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating an angiotensin receptor blocker as an anti-fibrotic treatment for chronic Hepatitis C was withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Angiotensin receptor blocker (angiotensin receptor blocker)

Snippet

Sponsor: Kaiser Permanente | Conditions: Hepatitis C | Phase 2 | Status: WITHDRAWN